Efficacy and safety of oral desmopressin in the treatment of primary nocturnal enuresis in Asian children
Abstract
Objective:
To determine the efficacy and safety of oral desmopressin (DDAVP) treatment in Asian children with nocturnal enuresis.
Methodology:
This was a multicentre randomized placebo-controlled double-blind cross-over study. Patients were randomized to either active treatment with oral 400 mg DDAVP or placebo, with a 2-week medication-free period between the cross-over. Children with primary monosymptomatic nocturnal enuresis, aged between 7 and 18 years, with a minimum frequency of wetting of 6 nights or more during a 2-week observation period were recruited. Efficacy was measured by reduction in the average number of wet nights per week.
Results:
Of the 37 children initially recruited, the outcomes for 34 children were included in the final cross-over analysis, as they had complete data for both the treatment periods. Statistical analysis by anova showed that there was no significant difference between the medication-free period and the pretreatment period. However, the average number of wet nights per week for the DDAVP treatment period (2.5±2.7) was significantly lower than that of the placebo treatment period (4.5±2.1) (P<0.0001). In terms of the safety profile, there was no significant change in bodyweight, blood pressure, serum sodium, serum osmolality, and urine osmolality following DDAVP treatment.
Conclusion:
Oral DDAVP is a safe and efficacious drug for the short-term treatment of children with primary nocturnal enuresis.
